{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:40:32Z","timestamp":1765528832168,"version":"3.48.0"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2016-0039_s_999_w2aab3b8c14b1b7b1aab1c15b1Aa\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The aim of this randomized clinical trial (RCT) was to evaluate the effect of vitamin D supplementation in obese, insulin-resistant (IR) and vitamin D-deficient polycystic ovary syndrome (PCOS) women on metabolic abnormalities in comparison to the effect of metformin or combined metformin plus vitamin D therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2016-0039_s_998_w2aab3b8c14b1b7b1aab1c15b2Aa\">\n                    <jats:title>Material and methods:<\/jats:title>\n                    <jats:p>Thirty-nine PCOS women who fulfilled the inclusion criteria were randomized into three groups and treated with alfacalcidiol, combined alfacalcidiol and metformin therapy and metformin for 6 months. Body weight, body mass index (BMI), waist circumference, total body fat and fat distribution were measured before and after 6 months of treatment. Plasma fasting glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR) and lipid profiles were measured at the same time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2016-0039_s_997_w2aab3b8c14b1b7b1aab1c15b3Aa\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There was a significant decrease in body weight, BMI, waist circumference, total body fat and serum glucose levels in the metformin group (p&lt;0.05), whereas PCOS women treated with alfacalcidiol did not significantly change their anthropometric and metabolic parameters. A significant decrease in waist circumference (p&lt;0.05) in the group treated with metformin and alfacalcidiol was detected without other significant metabolic changes (all p&gt;0.05). There were no significant changes in metabolic parameters (p&gt;0.05) after vitamin D therapy except for a slight but non-significant trend towards higher high-density lipoprotein (HDL) cholesterol levels (p=0.087).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2016-0039_s_996_w2aab3b8c14b1b7b1aab1c15b4Aa\">\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We conclude that vitamin D supplementation has no significant effect on anthropometric and metabolic parameters in PCOS women. Metformin has been still the most effective modality for the treatment of metabolic changes in PCOS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2016-0039","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T04:44:27Z","timestamp":1486097067000},"page":"85-91","source":"Crossref","is-referenced-by-count":9,"title":["The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome"],"prefix":"10.1515","volume":"29","author":[{"given":"Jana","family":"Figurov\u00e1","sequence":"first","affiliation":[{"name":"First Department of Internal medicine, Medical faculty of P.J.\u0160afarik University and L. P. University Hospital, Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Draveck\u00e1","sequence":"additional","affiliation":[{"name":"First Department of Internal medicine, Medical faculty of P.J.\u0160afarik University and L. P. University Hospital, Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Petr\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"First Department of Internal medicine, Medical faculty of P.J.\u0160afarik University and L. P. University Hospital, Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Javorsk\u00fd","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal medicine, Medical faculty of P.J.\u0160afarik University and L. P. University Hospital, Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivica","family":"Laz\u00farov\u00e1","sequence":"additional","affiliation":[{"name":"First Department of Internal medicine, Medical faculty of P.J.\u0160afarik University and L. P. University Hospital, Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,2,3]]},"reference":[{"key":"2025121207263004572_j_hmbci-2016-0039_ref_001_w2aab3b8c14b1b7b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544\u201351.","DOI":"10.1093\/humrep\/dep399"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_002_w2aab3b8c14b1b7b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; Androgen Excess Society. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society Guideline. J Clin Endoc Metab 2006;91:4237\u201345.","DOI":"10.1210\/jc.2006-0178"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_003_w2aab3b8c14b1b7b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012;33:981\u20131030.","DOI":"10.1210\/er.2011-1034"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_004_w2aab3b8c14b1b7b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011;95:1073\u20139.","DOI":"10.1016\/j.fertnstert.2010.12.027"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_005_w2aab3b8c14b1b7b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, Kimmig R, Mann K, Janssen OE. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2006;114:577\u201383.","DOI":"10.1055\/s-2006-948308"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_006_w2aab3b8c14b1b7b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, Obermayer-Pietsch B. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 2009;161:575\u201382.","DOI":"10.1530\/EJE-09-0432"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_007_w2aab3b8c14b1b7b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Yildizhan R, Kurdoglu M, Adali E, Kolusari A, Yildizhan B, Sahin HG, Kamaci M. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet 2009;280:559\u201363.","DOI":"10.1007\/s00404-009-0958-7"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_008_w2aab3b8c14b1b7b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Li HW, Brereton RE, Anderson RA, Wallace AM, Co HK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011;60:1475\u201381.","DOI":"10.1016\/j.metabol.2011.03.002"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_009_w2aab3b8c14b1b7b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Figurov\u00e1 J, Draveck\u00e1 I, Javorsk\u00fd M, Petr\u00edkov\u00e1 J, Laz\u00farov\u00e1 I. Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome and its relation to metabolic and reproductive abnormalities. Wien Klin Wochenschr 2016;128(17\u201318):641\u20138.","DOI":"10.1007\/s00508-015-0768-9"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_010_w2aab3b8c14b1b7b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and \u03b2-cell dysfunction. Am J Clin Nutr 2004;79:820\u20135.","DOI":"10.1093\/ajcn\/79.5.820"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_011_w2aab3b8c14b1b7b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Kotsa K, Yavropoulou MP, Anastasiou O, Yovos JG. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril 2009;92:1053\u20138.","DOI":"10.1016\/j.fertnstert.2008.07.1757"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_012_w2aab3b8c14b1b7b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Macut D, Pfeifer M, Yildiz BO, Diamanti-Kandarakis E. Polycystic ovary syndrome. Novel Insights into Causes and Therapy. Front Horm Res Basel: Karger, 2013;40:83\u2013102.","DOI":"10.1159\/isbn.978-3-318-02239-1"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_013_w2aab3b8c14b1b7b1ab2b2c13Aa","unstructured":"Wehr E, Pieber TR, Obermayer-Pietsch B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. J Endocrinol Invest 2011;34:757\u201363."},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_014_w2aab3b8c14b1b7b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Selimoglu H, Duran C, Kiyici S, Ersoy C, Guclu M, Ozkaya G, Tuncel E, Erturk E, Imamoglu S. The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Invest 2010;33:234\u20138.","DOI":"10.1007\/BF03345785"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_015_w2aab3b8c14b1b7b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids 1999;64:430\u201335.","DOI":"10.1016\/S0039-128X(99)00012-4"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_016_w2aab3b8c14b1b7b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Rashidi B, Haghollahi F, Shariat M, Zayerii F. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan J Obstet Gynecol 2009;48:142\u20137.","DOI":"10.1016\/S1028-4559(09)60275-8"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_017_w2aab3b8c14b1b7b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C, Vanderschueren D, Lips P. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. Clin Endocrinol Metab 2013;98:1283\u2013304.","DOI":"10.1210\/jc.2013-1195"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_018_w2aab3b8c14b1b7b1ab2b2c18Aa","unstructured":"Tehrani HG, Mostajeran F, Shahsavari S. The effect of calcium and vitamin D supplementation on menstrual cycle, body mass index and hyperandrognism state of women with polycystic ovarian syndrom. J Res Med Sci 2014;19:875\u201380."},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_019_w2aab3b8c14b1b7b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690\u20133.","DOI":"10.1093\/ajcn\/72.3.690"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_020_w2aab3b8c14b1b7b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Krul-Poel YH, Snackey C, Louwers Y, Lips P, Lambalk CB, Laven JS, Simsek S. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. Eur J Endocrinol 2013;169:853\u201365.","DOI":"10.1530\/EJE-13-0617"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_021_w2aab3b8c14b1b7b1ab2b2c21Aa","unstructured":"Bonakdaran S, Mazloom Khorasani Z, Davachi B, Mazloom Khorasani J. The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo- controlled clinical trial. Iran J Reprod Med 2012;10:465\u201372."},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_022_w2aab3b8c14b1b7b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Ardabilli HR, Gargari BP, Farzadi L. Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res 2012;32:195\u2013201.","DOI":"10.1016\/j.nutres.2012.02.001"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_023_w2aab3b8c14b1b7b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2010;53:2112\u20139.","DOI":"10.1007\/s00125-010-1838-1"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_024_w2aab3b8c14b1b7b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"P\u0142udowski P, Karczmarewicz E, Bayer M, Carter G, Chlebna-Sok\u00f3\u0142 D, Czech-Kowalska J, D\u0119bski R, Decsi T, Dobrza\u0144ska A, Franek E, G\u0142uszko P, Grant WB, Holick MF, Yankovskaya L, Konstantynowicz J, Ksi\u0105\u017cyk JB, Ksi\u0119\u017copolska-Or\u0142owska K, Lewi\u0144ski A, Litwin M, Lohner S, Lorenc RS, Lukaszkiewicz J, Marcinowska-Suchowierska E, Milewicz A, Misiorowski W, Nowicki M, Povoroznyuk V, Rozentryt P, Rudenka E, Shoenfeld Y, Socha P, Solnica B, Szalecki M, Ta\u0142a\u0142aj M, Varbiro S, \u017bmijewski MA. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol 2013;64:319\u201327.","DOI":"10.5603\/EP.2013.0012"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_025_w2aab3b8c14b1b7b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract 2009;15:438\u201349.","DOI":"10.4158\/EP09101.ORR"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_026_w2aab3b8c14b1b7b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"De Luca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(6 Suppl):1689\u201396.","DOI":"10.1093\/ajcn\/80.6.1689S"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_027_w2aab3b8c14b1b7b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Holick MF. Vitamin D Deficiency. N Engl J Med 2007;357:266\u201381.","DOI":"10.1056\/NEJMra070553"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_028_w2aab3b8c14b1b7b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Guillot X, Semerano L, Saidenberg-Kermanac\u2019h N, Falgarone G, Boissier MC. Vitamin D and inflammation. Joint Bone Spine 2010;77:552\u20137.","DOI":"10.1016\/j.jbspin.2010.09.018"},{"key":"2025121207263004572_j_hmbci-2016-0039_ref_029_w2aab3b8c14b1b7b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Plum AL, De Luca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 2010;9:941\u201355.","DOI":"10.1038\/nrd3318"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/hmbci.2017.29.issue-3\/hmbci-2016-0039\/hmbci-2016-0039.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2016-0039\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2016-0039\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:36:00Z","timestamp":1765528560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2016-0039\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,3]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,7,14]]},"published-print":{"date-parts":[[2017,3,1]]}},"alternative-id":["10.1515\/hmbci-2016-0039"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2016-0039","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"type":"electronic","value":"1868-1891"},{"type":"print","value":"1868-1883"}],"subject":[],"published":{"date-parts":[[2017,2,3]]}}}